CORCEPT THERAPEUTICS INC
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
CORT$73.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $138,004 | $75,364 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 81,902 | 63,732 |
| Accretion of marketable securities, net | (2,263) | (4,010) |
| Depreciation and amortization | 2,487 | 1,408 |
| Deferred income taxes | (618) | (22,355) |
| Changes in operating assets and liabilities: | ||
| Trade receivables | (51,275) | (15,653) |
| Inventory | (12,595) | (7,964) |
| Prepaid expenses and other current assets | 2,396 | (17,132) |
| Accounts payable | (18,535) | 19,070 |
| Accrued research and development expenses | (15,905) | (5,546) |
| Accrued and other liabilities, current and non-current | 36,064 | 16,634 |
| Net cash provided by operating activities | 159,662 | 103,548 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,438) | (161) |
| Proceeds from sales and maturities of marketable securities | 216,352 | 257,536 |
| Purchases of marketable securities | (369,600) | (175,774) |
| Net cash (used in) provided by investing activities | (156,686) | 81,601 |
| Cash flows from financing activities: | ||
| Proceeds from stock option exercises, net of issuance costs | 26,689 | 13,008 |
| Proceeds from purchases under the Employee Stock Purchase Plan (“ESPP”) | 9,059 | 7,160 |
| Repurchases of common stock in connection with Stock Repurchase Program | (5,745) | (172,915) |
| Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants | (55,165) | (36,403) |
| Net cash used in financing activities | (25,162) | (189,150) |
| Net effect of exchange rate changes on cash, cash equivalents and restricted cash | (172) | 1,474 |
| Net decrease in cash, cash equivalents and restricted cash | (22,358) | (2,527) |
| Cash, cash equivalents and restricted cash, at beginning of period | 121,745 | 128,665 |
| Cash, cash equivalents and restricted cash, at end of period | $99,387 | $126,138 |
| Supplemental disclosure: | ||
| Exercise cost of shares repurchased for net settlement of cashless option exercises | $38,554 | $17,799 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $98,720 | $125,138 |
| Restricted cash included in Other assets | 667 | 1,000 |
| Cash, cash equivalents and restricted cash, at end of period | $99,387 | $126,138 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.